Search results
Results from the WOW.Com Content Network
Activation of a wide range of serotonin receptors by serotonin itself or by certain prokinetic drugs results in enhanced gastrointestinal motility. [3] Other prokinetic drugs may increase acetylcholine concentrations by stimulating the M 1 receptor which causes acetylcholine release, or by inhibiting the enzyme acetylcholinesterase which ...
The most common side effects reported with naltrexone are gastrointestinal complaints such as diarrhea and abdominal cramping. [3] These adverse effects are analogous to the symptoms of opioid withdrawal, as the μ-opioid receptor blockade will increase gastrointestinal motility. The side effects of naltrexone by incidence are as follows: [3]
[25] [26] [2] However, it is available in the United States for people with severe and treatment-refractory gastrointestinal motility problems under an expanded access individual-patient investigational new drug application. [25] An analogue of domperidone called deudomperidone is under development for potential use in the United States and ...
These medications cause profound abnormalities of the gastrointestinal tract, breathing difficulties, and a sequence of problems leading to infections, skin breakdown, and nutritional deficiencies ...
Generally, drugs outlined within the ATC code A should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Gastrointestinal system drugs .
Cisapride is a gastroprokinetic agent, a drug that increases motility in the upper gastrointestinal tract. It acts directly as a serotonin 5-HT 4 receptor agonist and indirectly as a parasympathomimetic. Stimulation of the serotonin receptors increases acetylcholine release in the enteric nervous system.
There are two drug-binding α 2 δ subunits, α 2 δ-1 and α 2 δ-2, and most gabapentinoids show similar affinity for (and hence lack of selectivity between) these two sites. [1] In most cases, gabapentinoid drugs do not seem to directly alter the action of VGCC and instead reduce the release of certain excitatory neurotransmitters. [2 ...
Mosapride is a gastroprokinetic agent that acts as a selective 5HT 4 agonist.The major active metabolite of mosapride, known as M1, additionally acts as a 5HT 3 antagonist, [1] which accelerates emptying throughout the whole of the gastrointestinal tract in humans, [2] and is used for the treatment of gastritis, gastroesophageal reflux disease, functional dyspepsia [3] and irritable bowel ...